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Abstract  
Heart failure (HF) with preserved left ventricular (LV) ejection fraction (HFpEF) occurs in 40 to 60% 
of the patients with HF, with a prognosis which is similar to HF with reduced ejection fraction 
(HFrEF). HFpEF pathophysiology is different from that of HFrEF, and has been characterized with 
diastolic dysfunction. Diastolic dysfunction has been defined with elevated left ventricular stiffness, 
prolonged iso-volumetric LV relaxation, slow LV filing and elevated LV end-diastolic pressure. 
Arterial hypertension occurs in majority cases with HFpEF worldwide. Patients are mostly older and 
obese. Diabetes mellitus and atrial fibrillation appear proportionally in a high frequency of patients 
with HFpEF. The HFpEF diagnosis is based on existence of symptoms and signs of heart failure, 
normal or approximately normal ejection and diagnosing of LV diastolic dysfunction by means of 
heart catheterization or Doppler echocardiography and/or elevated concentration of plasma 
natriuretic peptide. The present recommendations for HFpEF treatment include blood pressure 
control, heart chamber frequency control when atrial fibrillation exists, in some situations even 
coronary revascularization and an attempt for sinus rhythm reestablishment. Up to now, it is 
considered that no medication or a group of medications improve the survival of HFpEF patients. 
Due to these causes and the bad prognosis of the disorder, rigorous control is recommended of the 
previously mentioned precipitating factors for this disorder. This paper presents a universal review 
of the most important parameters which determine this disorder. 
 
 
 
 
 
 
Introduction 
 
Beside contemporary treatment modalities, 
the heart failure (HF) is still a progressive disorder 
with a high morbidity and mortality rate [1]. Because of 
a great number of older people worldwide, it is 
expected that the incidence and the prevalence of the 
heart failure (HF) will increase rapidly in the next 
decade [2]. Beside the improvement of medical 
treatment, the mortality rate from this disorder has 
been still unacceptably high and becomes a leading 
cause for death in older people [1].
 
A great number of 
studies proved the most frequent risk-factors, being 
associated with the appearance of HF, such as 
advanced age, hypertension and ischemic heart 
disease [2].  
In about 50% of the patients having the 
symptoms and signs for heart failure, normal or 
approximately normal values of ejection fraction, when 
a separate clinical entity was isolated, called a heart 
failure with preserved ejection fraction (HFpEF). 
Numerous studies point the fact that it is a disorder 
with a complex pathophysiology, on which progress 
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and prognosis impact more cardiovascular 
disturbances [1]. It is expected that in the next decade 
HFpEF will become a dominant cause for heart failure 
worldwide, and due to that it becomes a provocative 
and important healthy problem for which, still, no 
treatment has been established, which will improve 
the prognosis of this disorder [1]. 
Up to now, it is considered that no medication 
or a group of medications improve the survival of 
HFpEF patients. Due to these causes and the bad 
prognosis of the disorder, rigorous control is 
recommended of the previously mentioned 
precipitating factors for this disorder. This paper 
presents a universal review of the most important 
parameters which determine this disorder. 
 
 
Material and Methods 
 
Investigations in medical electronic data basis 
(Pub Med, Google Scholar, Plos, and Elsevier) 
showed a great number of articles, especially in the 
last decade, which analyzed these subjects. In this 
review, 28 articles are cited, all published in the 
indexed world journals.  
Years backwards, the treatment of the heart 
failure was directed towards treatment of systolic 
dysfunction [3]. Historically viewed, a systolic 
dysfunction with EF < 45% was considered for heart 
failure. In line with Roelandt, the first association 
between myocardial relaxation and ventricular 
function was described in 1923 by Yendel Handerson, 
who presented data that myocardial relaxation was 
equally important as well as the contraction [4]. 
Gaasch defined the term “systolic dysfunction” in 1994 
as “the inability of the heart to adapted to the blood 
volume during diastole and the ventricular filing was 
delayed and incomplete, the atrial pressure was 
growing, causing pulmonary or systemic congestion”. 
Ten years later, in 2004, the same author “redefined” 
this entity adding “diastolic dysfunction could occur 
when the ejection fraction was normal or disturbed”. In 
1980, medical publicity started to recognize the 
symptoms and signs for heart failure in patients with 
normal ejection fraction [3]. Contrary to HFrEF, the 
individuals with HFpEF were generally older, more 
frequently women, and had increased incidence for 
developing hypertension, diabetes, coronary arterial 
disease, obesity and atrial fibrillation [5]. 
Asymptomatic patients with hypertensive left 
ventricular hypertrophy that, by echocardiography, 
show normal ejection fraction and disturbed left 
ventricular filing, could be said to have diastolic 
dysfunction [6, 7]. If these patients develop 
intolerance to effort, dyspnea, with venous or 
pulmonary congestion, it is considered to have 
“diastolic heart failure” [8].  
Prevalence of diastolic heart failure is higher 
in people older than 75 years. The mortality rate in 
patients with diastolic heart failure ranges between 5 
and 8%, compared to the patients with systolic heart 
failure, in whom it ranges between 10 and 15%. 
Morbidity, including the frequency of hospitalizations, 
has been approximately equal in these two groups of 
patients [8].
 
I 
Figure 1: Results from the investigation of the cardiac mortality 
depending the grade of diastolic dysfunction. NYHA-functional class 
for heart failure; MAP medium atrial pressure; DD diastolic 
dysfunction [2, 7] 
 
In a greater cohort study – PREVEND - an 
analysis has been made for the causes of HFpEF 
occurring within the period of 11 years, the 
investigation showed that the advanced age, urinary 
albumin excretion, cystatin C and a history of atrial 
fibrillation were strongly indicated by occurrence of 
HFpEF. In the past two decades, the percent of the 
patients with preserved ejection fraction increased 
from 38% to 54% of all the cases with hearth failure 
and this percent was considered to increase 
progressively with aging of the population and with the 
increase of the prevalence of patients with 
hypertension, obesity and diabetes [2, 9].   
 
 
Pathophysiology 
 
Diastolic dysfunction, defined by increased 
left ventricular stiffness, prolonged the iso-volumetric 
LV relaxation; slow LV filing and elevated LV end-
diastolic pressure lie in the basis of HFpEF [6, 10].  LV 
diastole consists of iso-volumetric relaxation and 
ventricular filing. LV relaxation is an active process 
occurring due to energetically dependent intracellular 
calcium input in sarco-plasmatic reticulum, which 
concentration increases during systole [11]. LC is 
disturbed by diseases which disturb the energetic 
metabolism of calcium re-uptake such as myocardial 
ischemia and myocardial hypertrophy [6]. Aging, on its 
own, is directly connected with cardiac contractile 
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dysfunction, which is manifested with prolonged time 
duration of the left chamber relaxation and stress 
intolerance [9]. It is proved, in trials, that aging, on its 
own, leads to diastolic dysfunction, oxidative stress 
and protein modification [9]. Left ventricular filing as a 
dynamic phase of diastole has been disturbed most 
frequently due to myocardial fibrosis or hypertrophy 
[11].  
Myocardial fibrosis has been caused by 
humoral factors such as various types of cytokines, 
“growth factors” and hormones. In hypertensive 
HFpEF, the oxidative stress increases the angiotensin 
II secretion from the blood vessels walls, due to 
elevated blood pressure. This results in fibroblast 
activation and increased protein-1 production of the 
transforming “growth factor” from macrophages and 
activation of monocyte haemotaxic protein-1. This 
results in perivascular inflammation, which is 
considered as a cause for reactive myocardial fibrosis 
[11]. 
 
Figure 2: End-systolic relation pressure-volume is equal in normal 
heart and diastolic heart failure, but the end-diastolic relation 
pressure-volume is different [11] 
 
Ventricular filing in diastole has been defined 
by physical characteristics of the heart cavities, which 
establishes the relation between pressure and 
volume. These physical characteristics depend on 
ventricular compliance, which means that the relation 
among some volume variations, appropriately 
correspond with the pressure changes. If, small 
volume variations, cause significant changes in 
diastolic pressure for longer period, there is a 
tendency for the patients to develop venous 
congestion and diastolic heart failure [12]. 
When the left ventricular function has been 
disturbed, the heart “output” is decreased concerning 
the incomplete filing of the LC in diastole, and as a 
compensatory mechanism elevates the LC end-
diastolic pressure, consequently the left atrial 
pressure also elevates and as a final result a direct 
pulmonary congestion.  
In the recent years, the new studies changed 
the concept, which traditionally was associated with 
development of heart failure with preserved systolic 
function [13]. These studies showed that the heart 
failure with preserved systolic function was a separate 
entity, which pathophysiology was complex and not to 
the end elucidated, and which needed different clinical 
approach from that which was applied for heart failure 
with impaired ejection fraction. Diastolic dysfunction 
has a central role in pathophysiology of heart failure 
with preserved ejection fraction, although it, on its 
own, could not be a cause to develop a clinical picture 
of heart failure. In that sense, it is important to 
emphasize that there is a great number of patients 
who have diastolic dysfunction, are asymptomatic and 
do not have signs for heart failure, even more that the 
prevalence of diastolic dysfunction surpasses 25% of 
the general population [13]. Among the "extra hearth" 
disorders which are pointed in pathophysiology of the 
heart failure with preserved systolic function are: 
endothelial dysfunction, changes of the blood vessel 
walls and reduced vasodilatation reserve [6].
 
 
 
Diagnosis of heart failure with preserved 
ejection fraction (HFpEF) 
 
Recommendations for a diagnosis of heart 
failure with preserved ejection fraction (HFpEF) are 
proved by the European Society for Cardiology (ESC) 
in 2012 and by the American Academy of Cardiology 
(ACC/AHA) in 2013. The diagnosis of HFpEF is based 
on existence of symptoms and signs for heart failure, 
normal or approximately normal ejection fraction (EF > 
45-50%) and diagnosing of LV diastolic dysfunction by 
means of heart catheterization or Doppler 
echocardiography and/or elevated natriuretic peptide 
(BNP > 200 pg/ml) concentration As supplement were 
added the known criteria of the New York Heart 
Association (NYHA), which was more functional 
classification.  
Diagnosing of LV diastolic dysfunction has 
been made most frequently with Doppler 
echocardiography and/or  elevated  natriuretic peptide  
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Figure 3: Grades of diastolic dysfunction by means of pulsed wave mitral Doppler and tissue Doppler mitral annular measurement [17]  
 
concentration. Cardiac magnetic resonance imaging 
(CMRI) is a new modality for diagnosing of diastolic 
dysfunction [14].
  
Echocardiography is the most important 
diagnostic method in patients with heart failure, as to 
the fact that the physical exam, the electrocardiogram 
and the X-ray do not give sufficient information, to 
distinguish the systolic from diastolic heart failure [12]. 
Establishment of diastolic function of the left 
chamber is an integral routine element of the 
echocardiographic evaluation of each patient.  
Four grades of diastolic dysfunction are 
determined by echocardiography: First grade of 
diastolic dysfunction or disturbed relaxation (Е/А < 
0.8, DT > 200 ms, IVRT > 100 ms, S > D, е' < 8 cm/s, 
Ar-A < 30m sec). Second grade of diastolic 
dysfunction or pseudo-normalization (E/A 0.8-1.5, DT-
normal, S/D < 1, Ar-A > 30cm/s, E/е is increasing to 9-
12, can be bigger). Third to fourth grade of diastolic 
dysfunction or restrictive ventricular filing EA >2, IVRI 
<60 ms, DT <160 ms reduced or none, septal Е/ е' 
>15). In this grade, LC relaxation has been seriously 
disturbed while significantly increased the ventricular 
pressure.  
The flow through mitral valve in diastole 
depends on transvalvular pressure gradient [4]. In 
normal conditions, this gradient is maximal 
immediately after the mitral valve opening, when 
corresponds with E-wave. Then, a period of reduced 
transvalvular gradient follows, which denotes a null 
flow (diastasis). Atrial contraction, which follows after 
that, causes a new gradient and flow, which 
corresponds to A-wave. The E/A ratio is considered to 
be a primary indicator for diastole. If disturbance of 
ventricular relaxation occurs, it comes to reduction of 
transvalvular gradient at the beginning of diastole, 
which consequently leads to reduction of the E-wave. 
Due to this, the atrial discharge disturbs, as a result to 
that the atrial contraction should be stronger, which is 
manifested with elevation of the A-wave. E/A ratio 
changes which is characteristically for the first grade 
of diastolic dysfunction. If the left atrial pressure is 
elevated for longer time, it causes symptoms of 
intolerance for physical effort (second grade of 
diastolic dysfunction). In patients in whom the LV 
diastolic pressure is so elevated, in order to restrict 
the transvalvular flow during the atrial contraction and 
constantly elevated left atrial pressure, it is called the 
third or restrictive type of diastolic dysfunction which is 
manifested with harder intolerance for physical effort 
[4, 6]. 
The analysis of the flow through pulmonary 
veins by means of pulsed Doppler, is an indirect 
indicator for atrial pressure, which, in absence of 
mitral valvular change, corresponds to LV diastolic 
pressure [4]. Pulsed Doppler of pulmonary flow 
measures the “peak systolic“ (S), “peak anterograde 
diastolic” (D) and “peak atrial reversal“ (Ar) velocities 
in apical four-cavity space, which is a good indicator 
of diastolic dysfunction [17, 18].
 
Other important indicators of diastolic 
dysfunction are tissue Doppler mitral annular 
measurement as well as the left atrial (LA) volume 
measurement and LA functional discharge index [12]. 
The tissue Doppler (TDI) measures the mitral annular 
Veterovska Miljkovik & Spiroska. Heart Failure with Preserved Ejection Fraction 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
OA Maced J Med Sci. 2015 Sep 15; 3(3):521-527.                                                                                                                                                                        525 
 
velocities including the systolic, early diastolic (е') and 
late diastolic (a) annular velocity. Patients with (е') 
septal < 8 cm/s have disturbed left ventricular 
relaxation. The Association of Echocardiography in 
scope of the European Society of Cardiology 
regulated that the ratio E/е' < 8 has been 
characterized with normal left ventricular filing, while 
the E/е' > 15 denotes elevated left ventricular 
pressure during filing [12, 18].
  
 
Figure 4: Dopler of pulmonary vein [17]
 
 
Total atrial, passive and active fractions of 
discharge are reduced in patients with HFpEF 
compared to hypertensive patients with normal 
diastole function [12]. Many studies showed that the 
atrial volume and function were similar in patients with 
left ventricular hypertrophy and the control group, and 
were disturbed for 68% in patients with HFpEF [10]. 
Some studies indicated that LAFI /left-atrial functional 
index/, as well as B-natriuretic peptide concentration, 
were prognostic indicators within the survival time of 
the patients with HFpEF [12].  
Atrial function maybe is a key compensatory 
mechanism, which determines the course and 
prognosis of the HFpEF patients [21]. Left atrium 
dysfunction, measured through the left atrial functional 
index, is associated with increased number of 
hospitalizations [12, 22]. It was also showed, in 
studies, that compared to the B-natriuretic peptide and 
to Doppler verified diastolic heart failure, the left atrial 
functional index (LFI) has been a better predictive 
factor for development of symptomatic, stable, chronic 
heart failure in older population [9]. 
In the past years, several studies pointed the 
significant connection of some biomarkers by 
appearance of the heart failure subtypes [11]. In line 
with them, the plasma B-natriuretic peptide 
concentration in HFpEF was lower than in the patients 
with HFrEF [11]. Highly sensitive troponin T was 
significantly associated with development of HFrEF. 
On the other hand, the growing factor (GDF 15), 
cystatin C, and the urinary albumin excretion were 
significantly associated with development of HFpE [7].
 
 
 
Treatment modalities  
 
Beside the fact that HFpEF is a frequent form 
of heart failure, and its frequency is expected to be in 
significant rise in the next decades, regarding the 
greater number of older population, as well as the 
number of the accompanying cardiovascular 
disorders, such as hypertension and diabetes, its 
pathophysiology is no completely defined, which is the 
main reason for lacking an approved therapeutic 
protocol.  
Angiotensin-converting enzyme inhibitors 
(ACEI), angiotensin receptor blockers (ARB), beta-
blockers and statins are used in the HFpEF treatment. 
But even beside that, none of them is authorized in 
reduction of mortality rate and the HFpEF patients’ 
survival.  
Hypertension treatment is one of the most 
important factors in treatment of diastolic dysfunction 
[20]. Effective decrease of blood pressure reduces the 
left atrial and left end-diastole pressure, improves the 
LV relaxation and filling. Also, reduction of blood 
pressure reduced the LV hypertrophy and the risk for 
progression of heart failure is decreasing [22]. ACEI 
Perindopril was tested in a trial of 850 patients with 
HFpEF older than 70 years within the period of 26 
months. This trial did not show difference in mortality 
and/or the number of hospitalizations from heart 
failure in the examinees compared to the control 
group. CHARM study, which investigated the ARB 
Candesartan impact in 3023 patients (ЕF > 40%), but 
did not show reduction of cardiovascular death in 
HFpEF patients, only reduction of number of 
hospitalizations of the treated group compared to the 
control one. In the PRESERVE study, the group of 
patients who were treated by Irbesartan was 
investigated, and then compared to the control one, 
the mortality rate and hospitalizations did not differ 
between them. Having in mind the HFpEF 
pathophysiology, beta blockers could have an effect, 
such as: 1) to reduce the heart frequency, by what the 
diastolic duration continues and corresponding to that 
the time of ventricular filling; 2) to reduce the 
myocardial oxygen demand 3); to reduce the blood 
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pressure and bring to regression the LC hypertrophy 
[5]. In addition, there are not sufficient trials with these 
medications, which will prove, with certainty, their 
benefits on mortality reduction of the HFpEF patients.  
Aldosterone is found to play a role in 
occurrence of cardiac fibrosis [16]. It is found that the 
aldosterone level showed a rise with advance of the 
age [16]. Higher aldosterone concentrations were 
found in patients with diastolic heart failure, compared 
to the control group, but not so high, as in the patients 
with systolic heart failure. Also, aldosterone was found 
to increase the LV mass in hypertensive patients 
independently than the plasma renin activity [16]. 
Accordingly, blockade of aldosterone could improve 
the cardiac fibrosis and LV performances [16]. 
Efficacy and safety of the long term aldosterone 
receptor blockade in HFpEF patients was investigated 
in Aldo-DHF randomized, multicentric, prospective 
study. By this treatment, the study showed that the left 
ventricular diastolic function and the left ventricular re-
modeling improved, but, however, the intolerance for 
physical effort, the patients’ symptoms and the 
patients’ quality of life did not. In a study of 245 
patients having heart failure with ejection fraction 
>40%, treated with Carvedilol in standard doses within 
a period of 3.2 years, compared to the control group 
which was not treated with Carvedilol, the prognosis 
did not improve in HFpEF patients [24].
  
In Randomized Aldactone Evaluation Study, 
correlation was found between the clinical benefit from 
the spironolactone use on serum markers for cardiac 
fibrosis, but other studies were lacking, which, with 
certainty, would determine the place of aldosterone 
inhibitors in the treatment of HFpEF patients [16]. This 
indicated that the data-base of the total of 53878 
patients examined in 30 published studies (18 
randomized controlled and 12 observed studies), 
showed that combined therapy could improve the 
symptoms of the HFpEF patients, but not the mortality 
rate [10, 25]. New modalities of HFpEF treatment in 
future could depend on profound knowledge for 
pathophysiology of diastolic heart failure.  
Some new medications promise to be used in 
the treatment of HFpEF in future. Phospodiesterase 5 
inhibitors are considered to reduce LV and arterial 
stiffness, to improve the endothelial function and 
reduce the pulmonary vascular resistance /RELAX-
study/ [10, 26].
 
Alagebrium chloride is a new agent 
which, in experimental research in animals, was found 
to improve the ventricular and vascular compliance, to 
reduce the blood pressure and vascular stiffness [20, 
27].  
 
Prognosis and discussion 
Experimental studies being conducted 
worldwide in the past decade ruined the previous 
concept that the prognosis of the heart failure with 
preserved ejection fraction was better than that of the 
patients with reduced ejection fraction. The facts 
worry that the survival of the patients with heart failure 
with preserved ejection fraction was not better in the 
last decades, opposite to longer survival of the 
patients with systolic heart failure.  
In patients with heart failure, diastolic 
dysfunction is a bigger prognostic indicator for 
mortality than the ejection fraction [8, 27].  
There are controversies in literature 
concerning the terminology, such as “Diastolic heart 
failure” or Heart failure with preserved ejection 
fraction”. The authors who preferred the former term 
probably did not take into account the fact that some 
systolic disturbances almost always were present in 
the patients with diastolic heart failure which were 
frequently proved by echocardiography, which spoke 
that this was a complex phenomenon that should be 
viewed as one entity [11]. 
Diastolic and systolic heart failure should not 
be considered as completely separate entities, 
diastolic function is disturbed even in systolic heart 
failure and is considered that it stresses even more 
the intolerance to physical effort and determines the 
prognosis. 
 
Figure 5: Systolic and diastolic heart failure-two phenotypes with 
different pathophysiology that are together linked [11] 
 
On the other hand, systolic contractile 
disturbances measured by tissue Doppler are also 
detected in diastolic heart failure. Accordingly, it 
comes out that the heart failure is the only entity with 
two phenotypes, which complement to each other 
[11]. 
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